Available Guidance and Best Practices for Conducting Forced Degradation Studies

Dan W. Reynolds, PhD

Dan W. Reynolds, PhD, is a research investigator II in the chemical development analytical sciences department at GlaxoSmithKline, Five Moor Dr., PO Box 13398, Research Triangle Park, NC 27709.

,
Karen M. Alsante, PhD

Karen M. Alsante, PhD, is a senior research investigator at Pfizer Global Research and Development (Groton, CT).

,
Kevin L. Facchine, PhD

Kevin L. Facchine, PhD, is a team manager in the chemical development analytical sciences department at GlaxoSmithKline.

,
June F. Mullaney, PhD

June F. Mullaney, PhD, is vice-president at the pharmaceutical development technical operations at GlaxoSmithKline, Five Moore Dr., PO Box 13398, Research Triangle Park, NC 27709.

,
Michael G. Motto, PhD

Michael G. Motto, PhD, is a director in the analytical research and development department at Pfizer Global Research and Development (Groton, CT).

,
Todd D. Hatajik

Todd D. Hatajik is a scientist at Pfizer Global Research and Development (Groton, CT).

Pharmaceutical Technology, Pharmaceutical Technology-02-02-2002, Volume 26, Issue 2

Participants at a Pharmaceutical Research and Manufacturers of America workshop share their views about the acceptable analytical practices of conducting forced degradation studies.